Formed in 2015, TARGET PharmaSolutions was created as an outcome of the success of HCV-TARGET, a case study of the TARGET model in hepatitis C. HCV-TARGET was a partnership with academia, the FDA and industry established in 2011 by Dr. Michael Fried and Dr. David Nelson, which has enrolled 14,000+ patients across 60 sites in North America and Europe.
The evidence generated from HCV-TARGET has multiple applications, including being used by regulators to monitor post-marketing drug safety, by sponsors to support label expansion and to fulfill multiple post marketing commitments. In addition, it has helped inform national and international treatment guidelines, been used in payer dossiers, and has resulted in numerous high impact scientific presentations and publications.
To date, there have been a total of 9 manuscript publications and 28 abstract presentations of HCV-TARGET.
at a glance:
- Located in Durham, NC
- 9 Leading Pharmaceutical Company Partnerships
- 200+ Community & Academic Sites
- 6 Disease Communities
- 40 Publications with 70+ Unique Authors
- Key Opinion Leaders on Academic & Publication Steering Committees
Company Timeline
2011
HCV-Target
Feb. 2015
TARGET PharmaSolutions founded
July 2016
Launched NASH community
Oct. 2016
Launched PBC community
Jan. 2017
Launched HCC community
July 2017
Launched IBD community
Nov. 2017
Executed CRADA with FDA
Jan. 2018
Site expansion in Europe
Aug. 2018
Launched HBV community
Oct. 2018
Launched DERM community